(Pagoni et al., 2022) Microglial activation, in AD affected brain regions, as measured by TSPO-PET has been associated with neuropsychiatric symptoms in AD including depression and was a stronger predictor of these symptoms than either amyloid or tau (Aguzzoli C, data presented at AAIC, 2023). This evidence concerns the gene MAPT and Alzheimer disease.